Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children

Condition(s) targeted: Urological Surgery

Intervention: Administration of remifentanil and glycopyrrolate (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: University Hospital, Ghent

Official(s) and/or principal investigator(s):
Koen Reyntjens, MD, Principal Investigator, Affiliation: University Hospital, Ghent

Overall contact:
Koen Reyntjens, MD, Phone: 0032/(0)9/240.49.55, Email: k.reyntjens@UGent.be

Study to investigate the influence of remifentanil and glycopyrrolate on cardiac index and blood pressure in children. To differentiate between contractility and the effect of the circulating volume, some of the subjects will receive additional fluid. This will be evaluated using two transthoracic echocardiac exams within the first 30 min of anesthesia.

Official title: Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study

Primary outcome:

Cardiac index

Blood pressure

Minimum age: 1 Year. Maximum age: 6 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- ASA I and II children

- 1-6 years

- urological surgery

Exclusion Criteria:

- Cardiac disease

- Diabetes

Koen Reyntjens, MD, Phone: 0032/(0)9/240.49.55, Email: k.reyntjens@UGent.be

University Hospital Ghent, Ghent 9000, Belgium; Recruiting
Koen Reyntjens, MD, Phone: 0032/(0)9/240.49.55, Email: k.reyntjens@UGent.be
Koen Reyntjens, MD, Principal Investigator

Website of the University Hospital Ghent

Starting date: May 2006
Last updated: December 19, 2007